Neuronetics, Inc.

OVERVALUEDSTIM · NASDAQ · Healthcare
STIM·NASDAQ·Healthcare
OVERVALUED
Neuronetics, Inc.
40.3%downside
MARKET PRICE
$1.91
FAIR PRICE
$1.14
MARGIN
$0.77
UNDERVALUEDFAIROVERVALUED
P/E RATIO
N/A
DIV. YIELD
N/A
ROE
-138.9%
MARKET CAP
$133M
FPI
fairpriceindex.com

FAIR PRICE VALUATION

40.3%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$1.91

FAIR PRICE

$1.14

MARGIN

$0.77

UNDERVALUEDFAIROVERVALUED

P/E Ratio

N/A

Div. Yield

N/A

ROE

-138.9%

Average

Market Cap

$133M

Small-cap

NOW AVAILABLE

Get notified when STIM's fair price changes

Push notifications when STIM's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

3.5/ 10

Stable earnings and revenue and consistent growth trajectory, but weak profitability margins and below-average fundamental quality.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$0.91CONSERVATIVE ENTRY
$1.14FAIR PRICE
$1.91MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$0.91

Fair price × 0.80

DISTANCE

52.3%

Price to entry level

At the current price of $1.91, STIM trades 52.3% above the conservative entry level of $0.91. This entry level represents a 20% margin of safety below the calculated fair price of $1.14 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

Loading chart data...

P/E RATIO HISTORY

Loading chart data...

METHODOLOGY

How we calculate STIM's fair price

Neuronetics, Inc.'s fair price of $1.14 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.91, STIM trades 40.3% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting STIM's risk profile.

RELATIVE · 30%

Comparing STIM's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for STIM, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate STIM's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for STIM.

Explore on Bulios

FAQ

What is the fair price of STIM?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Neuronetics, Inc. is $1.14. At the current market price of $1.91, STIM trades 40.3% above its calculated fair value.

Is STIM overvalued or undervalued?+

Neuronetics, Inc. is currently overvalued based on our valuation model. The stock trades at $1.91, which is 40.3% above the fair price of $1.14.

What is the margin of safety for STIM?+

With a 20% margin of safety applied to the fair price of $1.14, the conservative entry level for STIM is $0.91. At the current market price of $1.91, the stock trades 52.3% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is STIM's fair price updated?+

We update fair price calculations for STIM daily after market close. The current fair price of $1.14 incorporates the latest market data and sector multiples.

What factors affect STIM's fair price calculation?+

STIM's fair price of $1.14 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -138.9%.

Is STIM a good buy right now?+

At $1.91, STIM trades 40.3% above our fair value estimate of $1.14. The stock is currently overvalued. ROE stands at -138.9% (average). Fair Price Index provides valuation data — always do your own research before investing.

Does STIM pay dividends?+

STIM does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.